Baxdrostat 2mg lowered systolic blood pressure by 15.7 mmHg (9.8 mmHg placebo-adjusted) from baseline, and was generally well tolerated with no unanticipated safety findings Full results presented at ...

Findings of reduced risks for mortality and major CVD suggest consideration of statins in all adults with type 2 diabetes, even in those with low short-term predicted CVD risk.

Oral semaglutide is now approved to reduce cardiovascular risk in high-risk type 2 diabetes patients, marking a first for oral GLP-1 receptor agonists. The SOUL trial showed a 14% relative risk ...

Short sleep onset latency (SOL) is linked to lower hypertension risk, challenging traditional views on sleepiness and cardiovascular health. Objective sleepiness without daytime symptoms may indicate ...